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Moamen M.O.M. Aly1,2†, Gerhard Glatting1,3*†, Lennart Jahnke3, Frederik Wenz3 and Yasser Abo-Madyan3,4Abstract
Purpose: To dosimetrically evaluate different breast SIB techniques with respect to target coverage and organs at
risk (OARs) doses.
Methods: Four IMRT techniques were compared in 12 patients. Three techniques employ tangential whole breast
irradiation with either two coplanar fields (T-2F), or four non-coplanar fields (T-NC), or one Volumetric Modulated
Arc Therapy (T-VMAT) for the boost volume. The fourth technique is a fully-modulated VMAT technique (f-VMAT).
Dosimetric parameters were compared for the boost and breast target volumes as well as OARs. Delivery efficiency
was analysed based on number of monitor units (MUs) and estimated delivery time.
Results: T-VMAT and f-VMAT ranked highest with respect to integral assessment of boost and breast treatment
quality measures. T-VMAT significantly outperformed f-VMAT with respect to ipsi-lateral lung and left-sided
patients’ heart volumes ≥ 5 Gy (35 % ± 5 % vs. 52 % ± 6 % and 11 % ± 5 % vs. 22 % ± 6 %, respectively). f-VMAT
significantly outperformed T-VMAT with respect to ipsi-lateral lung volume ≥ 20 Gy (13 % ± 2 % vs. 15 % ± 3 %)
and heart volume ≥ 30 Gy in left breast cancer (0 % ± 0 % vs. 1 % ± 1 %). T-VMAT and f-VMAT needed 442 ± 58
and 1016 ± 152 MUs, respectively.
Conclusions: The hybrid T-VMAT is considered the technique of choice due to its balance of quality, efficiency
and dose to OARs.
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Breast cancer is the most common cancer in women
worldwide as it is also the main cause of cancer death
among women globally [1]. The use of radiotherapy in
the adjuvant setting has shown to improve both local
control and overall survival in early stage breast cancer
patients [2]. The most common and traditional whole
breast radiotherapy technique uses two tangential fields
due to its efficiency in terms of sparing nearby organs at
risk (OARs) as well as technical simplicity in which
wedge filters are used to compensate patient’s surface ir-
regularity and reach a homogenous dose distribution.* Correspondence: gerhard.glatting@medma.uni-heidelberg.de
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creativecommons.org/publicdomain/zero/1.0/This technique has evolved over the last decade with the
introduction of multi-leaf collimators (MLC) to deliver
field-in-field (FIF) three-dimensional conformal (3D-CRT)
[3–6] or intensity modulated radiation therapy (IMRT)
variants [7–11].
Dose escalation to the tumour-bed by a sequential
boost reduces local recurrence [12] but prolongs the
treatment duration and significantly increases the risk of
moderate to severe breast fibrosis [13]. Alternatively,
simultaneously integrated boost (SIB) using a higher
dose per fraction to the tumour bed was shown to be
dosimetrically advantageous especially regarding dose
conformity of the boost volume [14, 15], more conveni-
ent due to the shorter treatment time and was recently
shown to be very well tolerated on the short and
medium terms [16–18].
Different radiotherapy delivery techniques were pro-
posed for SIB, including 3D-CRT with wedges or FIFe distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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[19], or volumetric modulated arc therapy (VMAT)
[23, 24]. A thorough comparison of all these techniques
is yet to be performed. In this planning study we compare
the dosimetric outcomes of three inversely planned tech-
niques for SIB delivery based on the standard two tan-
gential whole breast fields plus two coplanar boost fields
(T-2F), or four non-coplanar boost fields (T-NC), or one
boost VMAT arc (T-VMAT) as well as a fully modu-
lated VMAT (f-VMAT) for both the whole breast and
integrated boost volumes.
Materials and methods
Patient selection and image data
Twelve female breast cancer patients (6 right-sided and
6 left-sided), who were recently treated in the Depart-
ment of Radiation Oncology, University Medical Centre
Mannheim, Heidelberg University, were retrospectively
randomly selected. The computed tomography (CT)
data-sets were acquired on a CT-simulator (Brilliance
CT Big Bore, Philips, Cleveland, OH, USA) according to
the institution’s standard protocol in 5 mm slice thick-
ness, in supine position with the use of a wing board for
arm positioning above the head.
Target volumes and organs at risk delineation
Both breast volumes (the affected side, and the contra-
lateral breast (CBreast)) were delineated and cropped
5 mm inside the skin contour. Also, the ipsi-lateral lung
(ILung), contra-lateral lung (CLung), and heart were de-
lineated. The boost clinical target volume was delineated
by an experienced physician according to the scar, pre
and post-operative radiological changes within the breast
tissue, the surgical report and/or the presence of surgical
clips. A setup safety margin of 5 mm was automatically
added to this boost volume to create the boost planning
target volume (PTVboost). This safety margin was con-
strained to 5 mm behind the skin contour. The whole
breast volume subtracting the PTVboost was considered
the breast planning target volume (PTVbreast).
Beam setup and plan prescription
For each patient, four different IMRT plans were gener-
ated using a treatment planning system that employs a
Monte Carlo calculation algorithm (Monaco v3.3, Elekta
AB, Stockholm, Sweden). A prescribed dose of 64.4 Gy
to the PTVboost and 50.4 Gy to the PTVbreast in 28 frac-
tions was planned. The plans were created for a 6 MV
photon beam Elekta Synergy® linear accelerator with an
MLCi2. Except for the VMAT techniques, all other tech-
niques/beams were planned for step and shoot IMRT
delivery. Optimization was performed to get the best
plan for each technique for each individual patient. The
optimization prescription aimed to deliver at least 92 %of the prescribed dose to 95 % of the target volumes and
to minimize the volume receiving ≥ 107 % of the boost
dose. Having reached these criteria for the targets, add-
itional effort was made to reduce dose to OARs indi-
vidually for each patient and planning technique starting
from the proper choice of gantry angles to the fine-
tuning of the prescription cost functions and tightening
the constraints to OARs. Our initial planning objectives
for the OARs were a mean dose below 5 Gy to the heart
for left sided cases, below 3 Gy for contralateral breast
and lung, a V20 below 22 % for ipsilateral lung. All plans
were normalized to deliver a median of 64.4 Gy to the
PTVboost volume.
For the first technique, two tangential beams (medial
and lateral tangents) were assigned to the PTVbreast and
another two coplanar oblique beams assigned to the
PTVboost with individually selected gantry angles to pre-
vent any unnecessary dose to OARs especially the ipsi-
lateral lung. These four fields were optimized together in
a single plan (T-2F).
The second technique consisted of the same tangential
beams assigned to the PTVbreast with four non-coplanar
beams assigned to the PTVboost (two gantry angles were
chosen for each of two extra couch angles, 45° and 315°)
aiming to further reduce OARs exposure, this, as an
adaptation from the technique described by Baglan et al.
2003 [25]. These six fields were optimized in a single
plan (T-NC).
The third technique was generated by creating a
hybrid of tangential IMRT and VMAT deliveries in a sin-
gle plan by assigning a single VMAT partial arc to the
PTVboost. The arc typically starts at the same gantry
angle assigned for the medial tangential beam and spans
(depending on the shape of the thoracic wall, PTVbreast
and location of the PTVboost) to a maximum of 240 °. In
this technique, the boost VMAT arc was firstly opti-
mized separately to deliver 14 Gy to the PTVboost and
then the resulted plan was used as a biased dose to the
tangential plan. The bias-dose option allows loading the
dose brought by the VMAT boost arc into the tangential
plan to account for it in the optimization of the tangen-
tial plan. This strategy leads to the reduction of breast
integral dose outside the boost volume. The combined
plan was named T-VMAT.
In these three techniques, each beam was assigned to
a specific target (i.e. tangential beams to the PTVbreast
and all other beams or arcs only to the PTVboost). Thus,
it was possible to prevent the inverse planning system
from using the non-tangential beams to target the whole
breast which avoids overexposure to the OARs. All these
plans were mono-isocentric with the isocentre placed in
the structure centre of the PTVbreast.
The fourth technique was generated using a fully mod-
ulated VMAT (f-VMAT) partial double arc, over a
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through the contra-lateral organs. In this technique, the
isocentre was placed on the centre of the PTVboost.
Plan evaluation
Plan evaluation was based on cumulative dose volume
histograms (DVHs). The conformity index (CI) and
homogeneity index (HI) for the PTVboost were calculated
for each plan using the radiation therapy oncology group
(RTOG) definitions [26] according to
CI¼ V 64:4
Vboost
ð1Þ
HI ¼ D2%
64:4
ð2Þ
where V64.4 is the volume of the prescription isodose
(64.4 Gy) surface and Vboost is the total boost target vol-
ume; D2% is the dose (Gy) received by 2 % of the boost
volume (maximum).
For the PTVbreast, the quality of coverage (Q) and the
heterogeneity index (hI) were calculated using
Q¼D98%
50:4
ð3Þ
hI¼ D2%
D98%
ð4Þ
where D98% and D2% are the doses (Gy) received by 98 %
(minimum) and 2 % (maximum) of the PTVbreast,
respectively.
Mean dose and volumes above 107 % (V107) and below
95 % (V95) of the prescribed doses for both target vol-
umes were also compared.
Mean dose and relative volume receiving ≥ 20 Gy (V20)
of the ILung [27] as well as mean dose and relative vol-
ume receiving ≥ 30 Gy (V30) of the heart were deter-
mined [28]. Furthermore, the mean dose received by the
CBreast and CLung were evaluated. To score for pre-
scribed dose and low dose spillage outside the PTVbreast,
two dose spillage indices (DSIs) were used as defined by
[23]
DSI50:4¼ V 50:4V PTV ð5Þ
DSI5¼ V 5VPTV ð6Þ
where V50.4 and V5 are the volumes of unspecified tissue
receiving ≥ 50.4 and ≥ 5 Gy, respectively, and VPTV is the
volume of PTVbreast.
To account for the low-dose bath and treatment effi-
ciency, OARs relative volumes’ receiving 5 Gy and
10 Gy, the total monitor units (MUs) and the estimated
beam-on time (as calculated from the planning systemfor a maximal dose rate of 600 MU/min) were recorded
and analysed for each planning technique.
Statistical analysis
Descriptive statistics of the data are presented as mean ±
standard deviation (SD). The differences of means
between the four plans were compared and analysed by
a repeated measures one-way ANOVA (with the
Greenhouse-Geisser correction and Tukey’s multiple
comparisons test) or the Friedman test (with Dunn’s
multiple comparisons test) using GraphPad Prism ver-
sion 6.04 for Windows (GraphPad Software, La Jolla
California USA, www.graphpad.com). Statistically sig-
nificant differences were assumed for a significance
level of p < 0.05.
Results
The PTVboost and PTVbreast volumes were (46 ± 25) cm
3
and (1107 ± 401) cm3, respectively. Figure 1 shows a
trans-axial CT slice with the dose distribution of the four
techniques and the corresponding cumulative DVHs for
a left-sided and a right-sided breast cancer patient. It
demonstrates that the four techniques were able to pro-
duce comparable results where the f-VMAT technique
achieves the relatively best coverage of the targets.
Table 1 shows the evaluation parameters of the two
targets for the studied techniques.V107 was equal to zero
for PTVboost in all techniques. For PTVbreast it ranged
from 10.4 % ± 1.3 % in f-VMAT technique to 18.7 % ±
7.1 % in T-NC technique, with the f-VMAT technique
being significantly lower than the 3 other techniques. All
techniques were able to record a V95 ≥ 95 % in PTVboost,
but the T-2 F recorded the lowest value (95.9 % ± 2.4 %).
Both T-2 F and T-NC V95 values were significantly lower
than that of T-VMAT technique in case of PTVboost and
T-2 F V95 was also significantly lower than f-VMAT in
the two target volumes. The T-VMAT technique was
significantly better than other techniques regarding
PTVboost mean dose, but not for HI, where the f-VMAT
technique was significantly better than other techniques.
Regarding the PTVbreast, the f-VMAT technique was sig-
nificantly better than the other techniques in mean dose,
Q, and hI except for Q in T-VMAT technique where
there was no significant difference.
Table 2 presents the results of all OARs dosimetric pa-
rameters. For ILung mean dose, T-2F was significantly
lower than both T-VMAT and f-VMAT, whereas for V20
only T-VMAT and f-VMAT showed a significant differ-
ence to each other. For left sided cancer patients, the
Heart V30 was lowest with f-VMAT. Significant differ-
ences between the four techniques were found only
between T-2F or T-VMAT and f-VMAT. On the other
hand, f-VMAT recorded significantly higher mean
cardiac dose than all other techniques in right-sided
Figure 1 A trans-axial CT slice and the corresponding DVHs of the breast two tangential fields with: two coplanar fields (T-2F), four non-coplanar
fields (T-NC), and a VMAT arc (T-VMAT) for the boost volume and a fully modulated VMAT (f-VMAT) techniques for a right-sided (right) and left-
sided (left) patient. The DVH line colours correspond to the structure colour
Table 1 The targets coverage multi-comparison analysis for all studied techniques (mean ± SD). Mean values with ǂ symbol demonstrate
that the corresponding technique did not pass the normality test. Friedman test of significance (p < 0.05) was used in these cases;
otherwise, repeated measures ANOVA significance test was used
N = 12 T-2F T-NC T-VMAT f-VMAT
PTVboost V107 (%) 0
* a 0* a 0* a 0* a
V95 (%) 95.9 ± 2.4
c 98.0 ± 0.9ǂ bc 99.3 ± 0.6a 98.6 ± 1.7ab
mean (Gy) 64.1 ± 0.1b 64.2 ± 0.0b 64.3 ± 0.0a 64.1 ± 0.1b
CI 0.50 ± 0.00a 0.50 ± 0.00a 0.50 ± 0.00a 0.50 ± 0.00a
HI 1.03 ± 0.01† a 1.03 ± 0.01† a 1.03 ± 0.01† a 1.02 ± 0.01† b
PTVbreast V107 (%) 18.1 ± 3.9
a 18.7 ± 7.1ǂ a 18.7 ± 4.2a 10.4 ± 1.3b
V95 (%) 94.5 ± 1.8
b 94.6 ± 1.9ab 95.5 ± 2.3ab 96.6 ± 1.6a
mean (Gy) 52.2 ± 0.3a 52.2 ± 0.5ǂ a 52.3 ± 0.5a 51.5 ± 0.2b
Q 0.91 ± 0.02b 0.91 ± 0.02b 0.92 ± 0.03ab 0.94 ± 0.02a
hI 1.36 ± 0.03† a 1.37 ± 0.04† a 1.34 ± 0.05† a 1.30 ± 0.03† b
a,b,c Values having the same superscript in the same horizontal line are not significantly different.
*All the 12 patients have a 0 value.
†Note that although these values look similar and have a comparatively small SD (between patients), the differences are significant due to individual patient’s
variability (i.e. when looking at the paired data)
V107 and V95 are volumes receiving 107 % and 95 % of prescribed dose respectively; CI, conformity index as defined by equation (1); HI, homogeneity index as
defined by equation (2); Q is the quality of coverage as defined by equation (3); hI, heterogeneity index as defined by equation (4)
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Table 2 The OARs multi-comparison analysis for all studied techniques (mean ± SD). Mean values with ǂ symbol demonstrate that
the corresponding technique did not pass the normality test. Friedman test of significance (p < 0.05) was used in these cases;
otherwise, repeated measures ANOVA significance test was used
N = 12 T-2 F T-NC T-VMAT f-VMAT
ILung V20 (%) 14.1 ± 3.5
ab 13.7 ± 3.5ab 14.8 ± 3.4ǂ a 13.3 ± 2.4ǂ b
mean (Gy) 8.4 ± 1.6c 8.8 ± 1.5abc 9.1 ± 1.5ab 9.5 ± 0.9ǂ a
Heart (Lt.) V30 (%) 1.3 ± 1.4
a 1.0 ± 0.9ab 1.2 ± 1.4ǂ a 0* ǂ b
mean (Gy) 3.0 ± 0.9b 2.8 ± 0.6b 3.5 ± 1.0ab 4.2 ± 0.4a
Heart (Rt.) V30 (%) 0
* a 0* a 0* a 0* a
mean (Gy) 1.8 ± 0.3b 1.6 ± 0.3ǂ b 1.9 ± 0.4b 2.6 ± 0.2a
CBreast mean (Gy) 1.1 ± 0.3c 0.9 ± 0.2d 1.2 ± 0.3ab 1.8 ± 0.4ǂ a
CLung mean (Gy) 0.9 ± 0.2ǂ bc 0.7 ± 0.1c 1.1 ± 0.2ab 1.8 ± 0.3ǂ a
Uns. Tissue DSI50.4 0.11 ± 0.05
ǂ a 0.10 ± 0.05ǂ a 0.16 ± 0.07a 0.02 ± 0.01b
DSI5 1.42 ± 0.26
b 1.31 ± 0.19b 1.38 ± 0.24b 2.65 ± 0.55a
a,b,c,d Values having the same superscript in the same horizontal line are not significantly different
*All the 12 patients have a 0 value
V20 and V30 are volumes receiving 20 Gy and 30 Gy respectively; DSI50.4 and DSI5 are the prescribed (50.4 Gy) and low dose (5 Gy) spillage indexes outside the
breast target volume
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patients. The f-VMAT technique also resulted in higher
CLung and CBreast mean doses than the other tech-
niques. The f-VMAT technique revealed the lowest
(best) DSI50.4 but the highest (worst) DSI5 compared to
all other techniques where the difference was significant.
Differences between the other three techniques were not
statistically significant.
Concerning all OARs low dose bath, f-VMAT revealed
a significantly higher ILung (V10 and V5) and left-sided
patients’ cardiac V5 than all other techniques (Table 3).
Table 4 shows the treatment efficiency parameters for
the four techniques. The f-VMAT technique had a sig-
nificantly higher number of MUs compared to the other
techniques. T-NC had a significantly higher estimated
beam-on time than f-VMAT.Table 3 The OARs low dose multi-comparison analysis for all studied
that the corresponding technique did not pass the normality test. Frie
otherwise, repeated measures ANOVA significance test was used
N = 12 T-2F
ILung V5 (%) 32.0 ± 5.4
c
V10 (%) 20.8 ± 4.5
b
Heart (Lt.) V5 (%) 6.9 ± 3.4
b
V10 (%) 3.3 ± 2.6
a
Heart (Rt.) V5 (%) 0.5 ± 0.3
a
V10 (%) 0
* a
CBreast V5 (%) 0.5 ± 0.7
ab
V10 (%) 0
* a
CLung V5 (%) 0.2 ± 0.5
ǂ ab
V10 (%) 0
* a
a,b,c,d Values having the same superscript in the same horizontal line are not signific
V5 and V10 are volumes receiving 5 Gy and 10 Gy respectivelyDiscussion
Exposing the tumour-bed to a higher dose per fraction
through SIB in a tumour with a supposedly low α/β ratio
[29], has presumably the potential to improve the local
control rates while reducing the overall treatment time
for patient convenience without increasing side effects
in an organ with a low α/β ratio. The possible downside
is an increase in breast fibrosis if large volumes are ex-
posed to a high dose per fraction (e.g. when boost vol-
umes are large compared to the breast volume). This
puts the focus on finding the optimal SIB technique that
adopts a radiobiologically sound dose fractionation
schedule through clinical trials [30]. The SIB concept in
treating breast cancer was originally presented by Freed-
man et al. [31] in 2007 showing acceptable cosmetic out-
come and quality of life, and was associated withtechniques (mean ± SD). Mean values with ǂ symbol demonstrate
dman test of significance (p < 0.05) was used in these cases;
T-NC T-VMAT f-VMAT
37.9 ± 5.2bc 35.1 ± 4.6b 52.1 ± 6.3a
21.0 ± 4.1b 21.9 ± 3.9ǂ b 25.0 ± 2.7ǂ a
7.7 ± 3.3b 10.9 ± 5.0b 22.0 ± 5.6a
2.6 ± 1.9a 3.6 ± 2.2ǂ a 3.3 ± 1.6a
0.5 ± 0.9ǂ a 1.5 ± 1.5a 0.7 ± 0.7a
0* a 0* a 0* a
0.0 ± 0.1ǂ b 0.4 ± 0.5ǂ a 0.6 ± 0.8 a
0* a 0* a 0* a
0.0 ± 0.0ǂ b 0.1 ± 0.3ǂ ab 0.4 ± 0.5ǂ a
0* a 0* a 0* a
antly different
Table 4 Treatment efficiency multi-comparison analysis for all studied techniques (mean ± SD). Mean values with ǂ symbol demonstrate
that the corresponding technique did not pass the normality test. Friedman test of significance (p < 0.05) was used in these cases;
otherwise, repeated measures ANOVA significance test was used
N = 12 T-2F T-NC T-VMAT f-VMAT
MU 425 ± 72ǂ b 411 ± 73ǂ b 442 ± 58b 1016 ± 152a
Estimated Treatment Time (min) 3.3 ± 0.7ab 3.3 ± 0.6ǂ b 2.8 ± 0.5ǂ ab 2.9 ± 1.5ǂ a
a,b,c Values having the same superscript in the same horizontal line are not significantly different
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A more recent early clinical report from a single centre
has reported acceptable rates of fibrosis within the boost
volume, mostly with very good cosmetic outcomes [16].
Loco-regional control and overall survival rates were
also reported to be excellent [18, 20]. Compared to the
most widely used sequential electron boost, IMRT-SIB
seems to have the advantages of better skin sparing and
boost volume conformity especially for deeper boost vol-
umes [14, 33].
Therefore, in search for the optimal breast-SIB radi-
ation technique, we thoroughly examined four modern
planning techniques derived from current common
practice. In terms of plan quality (homogeneity and con-
formity), all four techniques fulfilled the basic require-
ments and are considered applicable and clinically
acceptable. However, the assessment of superiority of
one technique over the other should be also based on
differences in risk of cardiac events, secondary cancers,
or fibrosis and treatment delivery efficiency. With the
common practice now shifting towards the use of hypo-
fractionated schemes with subsequent SIB dose per frac-
tion reaching 3.2 Gy, more focus has to be placed on
dosimetric quality of the chosen planning technique to
reduce potential side effects [24].
The use of inverse planning with selective targeting of
each target volume (selective assigning of tangential
beams to the PTVbreast and the extra beams to the
PTVboost) and, when appropriate, the use of biased-dose
concept have proven helpful in enhancing the dosimetric
qualities of the three tangential based techniques and
additionally reduced the differences between them. In
comparison to the reported dose values by Scorsetti
et al. [24], all our techniques produced lower mean
doses to the heart and contra-lateral OARs despite our
use of higher total target dose.
The increased risk of cardiac events after cardiac radi-
ation exposure has been the focus of many studies over
the past two decades. One of the most current
population-based analyses has estimated a linear in-
crease in risk of major coronary events by 7.4 % per
1 Gy increase in the mean radiation dose delivered to
the heart [34]. In this context, the f-VMAT technique
would be the most unfavourable with the highest mean
cardiac dose for right sided breast cancers, although the
difference to other techniques was generally not higherthan 1 Gy on average. For left sided cancer, only the
T-NC was significantly better than f-VMAT (but not
compared to the other investigated techniques). Again,
the difference in cardiac exposure was not higher than
1.4 Gy on average. Thus, the differences in cardiac risks
of all four techniques would be considered minor.
Radiation induced second cancers through whole body
exposure to a low-dose-bath (and increased scatter due
to higher MUs) with IMRT could also be an issue espe-
cially in younger patients. Hall et al. estimated the over-
all incidence to increase from 1 % after 3D-CRT to
1.75 % with IMRT for patients surviving 10 years [35].
Here, multiple factors come into play: an unconventional
increase in the total number of MUs with the subse-
quent increase in head leakage, higher exposure of many
internal organs especially of the contra-lateral breast and
lungs, and finally the need for image guided radiotherapy
with daily cone-beam-CT (CBCT) for a more accurate
patient’s breast set-up. All these factors are directly re-
lated to the use of highly modulated planning tech-
niques, especially with intensity-modulated arcs [36, 37].
In our study, we demonstrated the feasibility of keeping
the mean dose to the contra-lateral organs below 2 Gy
with the largest difference within all four techniques of
around 1 Gy on average, which could be considered
negligible. Nevertheless, the f-VMAT technique with ob-
viously the highest number of MUs, need for daily
CBCT, and significantly higher mean CBreast and
CLung doses should preferably be used only in older pa-
tients or young patients with challenging anatomy
(pectus excavatum, inclusion of parasternal lymph nodes
or cardiac contact to the chest wall) where the benefits
would outweigh the possible harms [38, 39].
The risk of breast fibrosis is influenced by the use of a
boost, of a higher single dose, and the dose per volume
[12, 40]. Therefore, special care should be taken to re-
duce the breast volume (outside the PTVboost) that re-
ceives doses above the prescription dose. In all four
examined techniques, f-VMAT has shown superiority
with significantly lower V107 and hI.
Regarding treatment efficiency, the estimated beam-on
time was around 3 min in all techniques (Table 4). Only
T-NC requires practically longer time to apply due to
the use of different couch angles.
Another very important aspect is the robustness, i.e.
the reproducibility of the prescribed dose distributions.
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nerable it becomes towards patient, breast setup errors
and breathing motions. A tangential IMRT setup was
shown to be dosimetrically as robust as conventional
wedged fields when a “flash margin” exists. A fully mod-
ulated IMRT without a flash margin delivery resulted in
under-dosage of the breast surface [41]. Thus, to im-
prove accuracy in the more complex techniques there
would be a higher demand to establish sufficient
immobilization and setup accuracy through the use of
image guidance (e.g. cone-beam CT or surface laser
scanners) and/or breath-hold or gating techniques.
The choice of the optimal technique should therefore
be performed based on the individual patient’s character-
istics; as there is no technique that is best with respect
to all criteria. T-VMAT and f-VMAT were in general the
best techniques with only a small difference in the mean
values. Thus, we recommend the hybrid T-VMAT tech-
nique for most of patients. Additionally, being coplanar
and tangential based, increases its robustness [42, 43]
and reduces low dose spillage outside the target in
comparison to f-VMAT with theoretically lower risks of
second cancers and cardiac events. T-2F might be the
simplest to plan and deliver, but when inversely opti-
mised to avoid dose spikes outside the boost volume
(thus being comparable to other multi-beamed tech-
niques) resulted in partial under-dosage within the boost
volume. T-NC has the advantage of marginally reducing
the low dose spillage thus reducing the mean dose in all
OARs. It is however the least practical in terms of
delivery and is more demanding in terms of setup accuracy
because of the non-coplanar nature of its setup.Conclusions
Modern radiotherapy techniques can deliver highly con-
formal dose distributions and can create different dose
levels within the treated volume. The implementation of
these advanced modalities needs to be simultaneously
optimized with respect to all possibly conflicting treat-
ment goals. Four IMRT breast-SIB techniques with dif-
ferent levels of complexity were explored. While all
techniques produced plans of clinically acceptable qual-
ity, the VMAT related techniques, f-VMAT and
T-VMAT, offered the best target coverage. The T-VMAT
would be considered the technique of choice for most
patients due to its robustness, practicality and offering a
most balanced mix between good target coverage and
homogeneity on the one hand versus dose scatter to the
OARs on the other hand. For individual cases with left
sided cancers and challenging geometry, f-VMAT may
be optimal.
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